Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel-Coated Balloon vs Zotarolimus-Eluting Stent for De Novo Coronary Lesions
NCT05209412Active, not recruiting
- Sponsor
- Xijing Hospital
- Start
- Feb 2022
- Primary completion
- Feb 2024
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Xijing Hospital. Primary endpoint: Coronary fraction flow reserve at 12 months. Started Feb 2022; status: active, not recruiting.
Beyond the preview
Go deeper on NCT05209412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05209412.